Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis

Journal of Medical Economics

Volumn 16, Issue 1, 2013, Pages 19-29

  Snedecor, Sonya J ^a   Carter, John A ^a   Kaura, Satyin ^b   Botteman, Marc F ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

Bone metastases; Cost effectiveness; Denosumab; Prostate cancer; Skeletal related event; Zoledronic acid

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MALE; QUALITY OF LIFE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DISEASE PROGRESSION; HEALTH EXPENDITURES; HUMANS; IMIDAZOLES; MALE; MARKOV CHAINS; MODELS, ECONOMETRIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84870928635     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.719054     Document Type: Article

References (35)

1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76 (Pubitemid 32452017)
2. Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
3. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population- based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14:177-83
4. Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 2011;7:381-3
5. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-22
6. Amgen. FDA Approves Amgen's XGEVA(TM) (Denosumab) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Amgen Press Release 2010. URL:http://www.amgen.com/media/ media-pr-detail.jsp? releaseID1498709. Accessed 9 March 2012
7. Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 2010
8. Aapro MS. Denosumab for bone metastases from breast cancer: A new therapy option? J Clin Oncol 2011;29(14):e419-20
9. Aragon-Ching JB. Unravelling the role of denosumab in prostate cancer. Lancet 2011;377:785-6
10. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value. J Clin Oncol 2011;29:1095-8
11. Wahed AS, Luong TM, Jeong JH. A new generalization of Weibull distribution with application to a breast cancer data set. Stat Med 2009;28:2077-94
12. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the ''DEALE''). I. Validation of the method. Am J Med 1982;73:883-8 (Pubitemid 13211834)
13. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537-42 (Pubitemid 38365413)
14. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84 (Pubitemid 40613323)
15. Ford J, Cummins E, Sharma P, et al. Systematic review of the clinical effectiveness and cost effectiveness and economic evaluation of denosumab for the treatment of bone metastases from solid tumors. Aberdeen: Aberdeen HTA Group, Institure of Applied Sciences, University of Aberdeen, 2011
16. Denosumab [Package Insert]. Thousand Oaks, CA: Amgen Incorporated, 2010
17. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
18. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84 (Pubitemid 46621802)
19. Snedecor SJ, Carter JA, Kaura S, et al. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Clin Ther 2012;34(6):1334-49
20. Barlev A, Chung K, Delea T, et al. Healthcare and utilization costs associated with skeletal related events in prostate cancer patients with bone metastases. J Manag Care Pharm 2010;16(9):693-702
21. National Fee Analyzer. Eden Prairie, MN: Ingenix Inc, 2011
22. Neighbors DM, Bell TJ, Wilson J, et al. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage 2001;21:129-43 (Pubitemid 32156943)
23. Moore S, Tumeh J, Wojtanowski S, et al. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10:23-31 (Pubitemid 46161092)
24. Klarenbach S, Manns B, Reiman T, et al. Economic evaluation of erythropoiesis- stimulating agents for anemia related to cancer. Cancer 2010;116:3224-32
25. Greenberg D, Earle C, Fang CH, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-8
26. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5 (Pubitemid 43261756)
27. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2000;18:72-9 (Pubitemid 30036338)
28. Sartor O. Denosumab in bone-metastatic prostate cancer: Known effects on skeletal-related events but unknown effects on quality of life. Asian J Androl 2011;13:612-3
29. Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res 2012 [Epub ahead of print]
30. Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15(4):712-23
31. Lothgren M, Bracco A, Lucius B, et al. Cost-Effectiveness of denosumab vs zoledronic acid (ZA) for the prevention of skeletal-related events (SRE) in patients with bone metastases from solid tumors in the Netherlands. International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress in Madrid, Spain. 2011
32. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: Analysis of a national medical claims database. Cancer 2008;113:1438-45
33. Hatoum HT, Lin SJ, Guo A, et al. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 2011;27:55-62
34. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-9
35. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32